In a welcome move, Bristol Myers Squibb saw its Relative Strength Rating improve from 70 to 76 on Tuesday. Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental ...

Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, ...

On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.Please watch the ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight ...

In this segment, Dr. Roxanna Mehran of the Mount Sinai Health System is talking about the Bristol-Myers Squibb-Janssen Librexia Clinical Trial Program. More information on the clinical trial and ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy now. The medical and healthcare industry is one of the ...

Amazon Prime confirmed on Thursday that former NBC News and MSNBC anchor Brian Williams, whose career was upended by an embarrassing reporting scandal in 2015, will be hosting an election night ...

Bristol-Myers Squibb Company (NYSE ... Additionally, approximately 10 assets in the Innovative Medicine area have the potential to produce anticipated operational sales of over $5 billion each.

Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies ...